| Stereochemistry | RACEMIC |
| Molecular Formula | C17H18N2.ClH |
| Molecular Weight | 286.799 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1C(CC2=C(C=CC=C2)N=C1C)C3=CC=CC=C3
InChI
InChIKey=RKGYKBFILSMGSV-UHFFFAOYSA-N
InChI=1S/C17H18N2.ClH/c1-13-18-16-11-7-6-10-15(16)12-17(19(13)2)14-8-4-3-5-9-14;/h3-11,17H,12H2,1-2H3;1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C17H18N2 |
| Molecular Weight | 250.3382 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Dazepinil (HRP 543) is a 1,3-benzodiazepine antidepressant, developed by Hoerscht in the early 1980s. In mouse tests, dazepinil inhibited tetrabenazine-induced ptosis and potentiated yohimbine toxicity. In vitro, dazepinil inhibited norepinephrine and serotonin uptake into rat brain synaptosomes and lacked anticholinergic activity.
Originator
Approval Year
PubMed
|
|
PARENT -> SALT/SOLVATE | |||
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
Showing 1 to 3 of 3 entries